Navigation Links
C8 MediSensors Files for CE Mark Approval, Advancing Plans for 2012 Product Introduction In Europe
Date:4/6/2012

SAN JOSE, Calif., April 6, 2012 /PRNewswire/ -- C8 MediSensors, Inc. (www.c8medisensors.com), the leader in developing non-invasive continuous glucose monitoring for people with diabetes, announced today that it has filed for CE mark approval to market the C8 MediSensors Optical Glucose Monitor™ in Europe. The monitor is currently an adjunct investigational device.

(Logo: http://photos.prnewswire.com/prnh/20120406/AQ83655LOGO)

"The European Union has over 30 million people with diabetes who strive for better glycemic control to improve their health. Continuous glucose monitoring helps achieve better glycemic control but unfortunately, current methods of continuous glucose monitoring can be painful and come with high ongoing costs year after year. We plan to address that problem with technology that allows people with diabetes to measure their glucose continuously but without the pain and cost of current invasive technologies," said Paul S. Zygielbaum, Chief Operating Officer of C8 MediSensors.

C8 MediSensors uses a proven technology, Raman spectroscopy, to accurately measure glucose trans-dermally. A pain-free beam of light enters the skin and measures the unique Raman fingerprint of the glucose molecule.  Readings are then sent to a display application on the user's smartphone.  The C8 MediSensors Optical Glucose Monitor has been in development for over eight years.

About C8 MediSensors

Headquartered in San Jose CA, C8 MediSensors' breakthrough patent-protected technology has been developed to give people with diabetes a continuous view of their glucose levels, without the pain, inconvenience and high cost of invasive continuous glucose monitoring. Visit www.c8medisensors.com.

This document contains forward-looking statements. Any statements contained in this document that are not statements of historical fact may be deemed to be forward- looking statements, including, without limitation, statements relating to the ability to commercially market any C8 MediSensors' anticipated products, sales and company financing needs. These forward-looking statements are based upon C8 MediSensors' current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks associated with obtaining CE mark approval, market conditions, customer demand for the product, and risks and uncertainties associated with C8 MediSensors' business and finances in general. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document. C8 MediSensors does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.


'/>"/>
SOURCE C8 MediSensors, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
4. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
7. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
8. FDA Files Application To Convert ONTAK(R) (Denileukin Diftitox) to Full Approval for Use in Cutaneous T-Cell Lymphoma (CTCL)
9. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
10. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
11. deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 2017 Research and Markets has announced the addition ... report to their offering. ... The latest research Menopause Drugs Price Analysis and Strategies - 2016, provides ... research answers the following questions: What are ... they positioned in the Global Menopause market? What are ...
(Date:2/23/2017)... , Feb. 23, 2017 Research and ... Analysis and Strategies - 2016" report to their offering. ... The latest research ... data and benchmarks in the global Fibromyalgia market. The ... the key drugs marketed for Fibromyalgia and their clinical attributes? How ...
(Date:2/23/2017)... 23, 2017 Obese people are ... for varicose veins in their body. The rising number ... the adoption of endovenous laser therapy for treatment of ... laser therapy market, published by Future Market Insights, ... and consequences of obesity have collectively factored the growth ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 24, 2017 , ... Congratulations to Head Over Heels’ elite ... 12th. Ms. Esparza qualified into this prestigious status after winning the Vault, ... Vegas, Nevada. Frida is one of approximately 25 gymnasts in the nation who ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most ... Jensie Gran Fondo of Marin. For the second year in a row, cyclists ... sunscreen. , “We are thrilled to provide our safe, non-toxic sunscreen to over ...
(Date:2/23/2017)... CO (PRWEB) , ... February 23, 2017 , ... The ... announce the winner of the 2016 National Education Policy Center Bunkum Award. We invite ... reviewed in 2016. , This year’s Bunkum winner is the Center for American Progress ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease ... will be participating in Rare Disease Day events, hosted by the Rare Disease ... Disease Report, a website, weekly e-newsletter and quarterly publication, will be conducting interviews ...
(Date:2/23/2017)... Angeles, CA (PRWEB) , ... February 23, 2017 , ... ... first two episodes of WE TV’s “Mama June: From Not to Hot,” which will ... TV notable, “Mama” June Shannon, known to millions from the 2012 reality television series, ...
Breaking Medicine News(10 mins):